|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL1RL1 |
Gene summary for IL1RL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL1RL1 | Gene ID | 9173 |
| Gene name | interleukin 1 receptor like 1 | |
| Gene Alias | DER4 | |
| Cytomap | 2q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q01638 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9173 | IL1RL1 | CA_HPV_1 | Human | Cervix | CC | 1.24e-19 | -5.36e-01 | 0.0264 |
| 9173 | IL1RL1 | CA_HPV_3 | Human | Cervix | CC | 1.91e-05 | -3.57e-01 | 0.0414 |
| 9173 | IL1RL1 | N_HPV_2 | Human | Cervix | N_HPV | 2.59e-05 | -3.72e-01 | -0.0131 |
| 9173 | IL1RL1 | CCI_1 | Human | Cervix | CC | 1.23e-03 | -5.79e-01 | 0.528 |
| 9173 | IL1RL1 | CCI_2 | Human | Cervix | CC | 3.50e-03 | -5.79e-01 | 0.5249 |
| 9173 | IL1RL1 | CCI_3 | Human | Cervix | CC | 1.82e-05 | -5.79e-01 | 0.516 |
| 9173 | IL1RL1 | CCII_1 | Human | Cervix | CC | 2.82e-08 | -5.79e-01 | 0.3249 |
| 9173 | IL1RL1 | Tumor | Human | Cervix | CC | 1.16e-23 | -5.79e-01 | 0.1241 |
| 9173 | IL1RL1 | sample1 | Human | Cervix | CC | 1.27e-06 | -5.79e-01 | 0.0959 |
| 9173 | IL1RL1 | sample3 | Human | Cervix | CC | 3.06e-19 | -5.51e-01 | 0.1387 |
| 9173 | IL1RL1 | H2 | Human | Cervix | HSIL_HPV | 8.15e-16 | -5.39e-01 | 0.0632 |
| 9173 | IL1RL1 | L1 | Human | Cervix | CC | 2.98e-09 | -5.79e-01 | 0.0802 |
| 9173 | IL1RL1 | T1 | Human | Cervix | CC | 2.01e-16 | -5.79e-01 | 0.0918 |
| 9173 | IL1RL1 | T2 | Human | Cervix | CC | 6.62e-03 | -5.79e-01 | 0.0709 |
| 9173 | IL1RL1 | T3 | Human | Cervix | CC | 2.48e-14 | -5.51e-01 | 0.1389 |
| 9173 | IL1RL1 | EOLP-1 | Human | Oral cavity | EOLP | 4.24e-11 | 5.44e-01 | -0.0202 |
| 9173 | IL1RL1 | EOLP-2 | Human | Oral cavity | EOLP | 2.15e-15 | 5.60e-01 | -0.0203 |
| 9173 | IL1RL1 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 2.31e-12 | -6.59e-01 | 0.02 |
| 9173 | IL1RL1 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 2.40e-10 | -6.59e-01 | 0.0267 |
| 9173 | IL1RL1 | PTCwithHT_6 | Human | Thyroid | HT | 4.35e-12 | -6.32e-01 | 0.02 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:00026837 | Cervix | CC | negative regulation of immune system process | 94/2311 | 434/18723 | 2.63e-08 | 1.87e-06 | 94 |
| GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
| GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
| GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
| GO:00507294 | Cervix | CC | positive regulation of inflammatory response | 34/2311 | 142/18723 | 9.51e-05 | 1.25e-03 | 34 |
| GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
| GO:00507773 | Cervix | CC | negative regulation of immune response | 41/2311 | 194/18723 | 3.63e-04 | 3.76e-03 | 41 |
| GO:00026967 | Cervix | CC | positive regulation of leukocyte activation | 72/2311 | 409/18723 | 1.13e-03 | 9.31e-03 | 72 |
| GO:00508676 | Cervix | CC | positive regulation of cell activation | 73/2311 | 420/18723 | 1.50e-03 | 1.16e-02 | 73 |
| GO:00024603 | Cervix | CC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 62/2311 | 356/18723 | 3.09e-03 | 2.03e-02 | 62 |
| GO:00421163 | Cervix | CC | macrophage activation | 23/2311 | 106/18723 | 4.65e-03 | 2.81e-02 | 23 |
| GO:0002819 | Cervix | CC | regulation of adaptive immune response | 35/2311 | 183/18723 | 5.38e-03 | 3.11e-02 | 35 |
| GO:00022743 | Cervix | CC | myeloid leukocyte activation | 41/2311 | 223/18723 | 5.66e-03 | 3.25e-02 | 41 |
| GO:0002822 | Cervix | CC | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 32/2311 | 168/18723 | 8.00e-03 | 4.18e-02 | 32 |
| GO:000269611 | Cervix | HSIL_HPV | positive regulation of leukocyte activation | 44/737 | 409/18723 | 1.58e-09 | 3.04e-07 | 44 |
| GO:005086711 | Cervix | HSIL_HPV | positive regulation of cell activation | 44/737 | 420/18723 | 3.59e-09 | 5.76e-07 | 44 |
| GO:005072711 | Cervix | HSIL_HPV | regulation of inflammatory response | 41/737 | 386/18723 | 8.30e-09 | 1.03e-06 | 41 |
| GO:000246011 | Cervix | HSIL_HPV | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 37/737 | 356/18723 | 7.84e-08 | 5.32e-06 | 37 |
| GO:003210312 | Cervix | HSIL_HPV | positive regulation of response to external stimulus | 41/737 | 427/18723 | 1.40e-07 | 9.01e-06 | 41 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| IL33 | IL1RL1_IL1RAP | IL33_IL1RL1_IL1RAP | IL1 | HNSCC | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL1RL1 | SNV | Missense_Mutation | c.1057N>C | p.Phe353Leu | p.F353L | Q01638 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| IL1RL1 | SNV | Missense_Mutation | novel | c.1129N>A | p.Tyr377Asn | p.Y377N | Q01638 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| IL1RL1 | SNV | Missense_Mutation | c.491N>T | p.Ser164Leu | p.S164L | Q01638 | protein_coding | tolerated(0.09) | benign(0.438) | TCGA-BH-A18J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| IL1RL1 | SNV | Missense_Mutation | c.971N>A | p.Ile324Asn | p.I324N | Q01638 | protein_coding | tolerated(0.14) | benign(0.001) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| IL1RL1 | insertion | Frame_Shift_Ins | novel | c.1483_1484insCACAAAA | p.Leu496GlnfsTer27 | p.L496Qfs*27 | Q01638 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| IL1RL1 | insertion | Frame_Shift_Ins | novel | c.1485_1486insGGTTCTCTATCCACACATATCTCCA | p.Leu496GlyfsTer33 | p.L496Gfs*33 | Q01638 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| IL1RL1 | SNV | Missense_Mutation | rs765447417 | c.44C>T | p.Ser15Phe | p.S15F | Q01638 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IL1RL1 | SNV | Missense_Mutation | novel | c.826T>G | p.Phe276Val | p.F276V | Q01638 | protein_coding | tolerated(0.49) | benign(0.02) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IL1RL1 | SNV | Missense_Mutation | rs747107463 | c.393N>G | p.Ile131Met | p.I131M | Q01638 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| IL1RL1 | SNV | Missense_Mutation | novel | c.281N>A | p.Phe94Tyr | p.F94Y | Q01638 | protein_coding | tolerated(1) | benign(0.014) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |